Abukhalil Abdallah Damin, Abushehadeh Raya Riyad, Shatat Sireen Sultan, Al-Shami Ni'meh, Naseef Hani A, Ladadweh Hosniyeh, Madia Raed
Faculty of Pharmacy, Nursing and Health Professions, Birzeit University, Birzeit, West Bank, Palestine.
Int J Gen Med. 2024 Jul 30;17:3349-3360. doi: 10.2147/IJGM.S466838. eCollection 2024.
Coronavirus disease (COVID-19) vaccines play an essential role in boosting immunity, preventing severe diseases, and alleviating the Covid-19 health crisis.
This study aimed to explore the type and severity of short-term adverse reactions associated with BNT162 (Pfizer-BioNTech), mRNA 1273 (Moderna), and viral vector vaccines and to compare the incidence of post-vaccination Covid-19 infection among the Birzeit University community in Palestine.
This questionnaire-based retrospective cross-sectional study was conducted among individuals who were vaccinated with at least one dose of any COVID-19 vaccine offered in Palestine during the COVID-19 pandemic. The study included participants aged 18 years and older who were vaccinated with Pfizer, Moderna, Sputnik Light, or Sputnik v.
A total of 558 participants who were administered COVID-19 vaccine were included in the study. Sputnik (239), Pfizer vaccine recipients (236), and Moderna vaccine recipients (83). Of the viral vector vaccine recipients, 57 (23.8%) had a post-vaccination infection, compared to 30 (12.7%) for Pfizer and seven (8.4%) for Moderna. Furthermore, the reported adverse effects in the viral victor group were higher than those in the Moderna and Pfizer groups (71.7, 66.3, and 61.9%, respectively). Chills, headache, fatigue, abdominal pain, and joint pain were significantly higher in the Viral Vector vaccine group than the Moderna and Pfizer vaccine. Vomiting, tiredness, and fatigue were significantly less likely to be complained of by Pfizer vaccine recipients compared to Moderna and Viral Vector vaccine recipients (p < 0.05).
Breakthrough infections were associated with both viral vectors and mRNA; however, the mRNA vaccine had less reported post-vaccine infection. Furthermore, the Pfizer/BioNTech COVID-19 vaccine group reported fewer commonly reported side effects (fever, chills, headache, fatigue, muscle pain, joint pain, nausea, and dizziness), followed by the Moderna and viral vector vaccines. Females and underweight participants experienced more adverse effects with both vaccines, and fewer common side effects were reported by all participants.
冠状病毒病(COVID-19)疫苗在增强免疫力、预防重症以及缓解COVID-19健康危机方面发挥着重要作用。
本研究旨在探究与BNT162(辉瑞 - 生物科技公司)、mRNA 1273(莫德纳公司)和病毒载体疫苗相关的短期不良反应的类型和严重程度,并比较巴勒斯坦比尔宰特大学社区接种疫苗后COVID-19感染的发生率。
这项基于问卷的回顾性横断面研究是在COVID-19大流行期间接种了巴勒斯坦提供的至少一剂任何COVID-19疫苗的个体中进行的。该研究纳入了年龄在18岁及以上且接种了辉瑞、莫德纳、卫星V轻型或卫星V疫苗的参与者。
共有558名接种了COVID-19疫苗的参与者被纳入研究。其中接种卫星V疫苗的有239人,接种辉瑞疫苗的有236人,接种莫德纳疫苗的有83人。在病毒载体疫苗接种者中,57人(23.8%)在接种后感染,而辉瑞疫苗接种者中有30人(12.7%),莫德纳疫苗接种者中有7人(8.4%)。此外,病毒载体组报告的不良反应高于莫德纳组和辉瑞组(分别为71.7%、66.3%和61.9%)。病毒载体疫苗组的寒战、头痛、疲劳、腹痛和关节痛明显高于莫德纳疫苗组和辉瑞疫苗组。与莫德纳疫苗接种者和病毒载体疫苗接种者相比,辉瑞疫苗接种者抱怨呕吐、疲倦和疲劳的可能性明显更小(p < 0.05)。
突破性感染与病毒载体疫苗和mRNA疫苗都有关;然而,mRNA疫苗接种后感染的报告较少。此外,辉瑞/生物科技公司的COVID-19疫苗组报告的常见副作用(发热、寒战、头痛、疲劳、肌肉疼痛、关节疼痛、恶心和头晕)较少,其次是莫德纳疫苗和病毒载体疫苗。女性和体重不足的参与者接种两种疫苗后不良反应更多,所有参与者报告的常见副作用较少。